ANL 34.25 Increased By ▲ 0.61 (1.81%)
ASC 13.35 Decreased By ▼ -0.05 (-0.37%)
ASL 22.60 Increased By ▲ 0.10 (0.44%)
AVN 83.70 Decreased By ▼ -0.74 (-0.88%)
BOP 7.70 Increased By ▲ 0.05 (0.65%)
BYCO 9.37 Decreased By ▼ -0.01 (-0.11%)
DGKC 110.20 Increased By ▲ 0.52 (0.47%)
EPCL 50.89 Increased By ▲ 0.64 (1.27%)
FCCL 22.76 Decreased By ▼ -0.02 (-0.09%)
FFBL 25.70 Increased By ▲ 0.09 (0.35%)
FFL 15.30 No Change ▼ 0.00 (0%)
HASCOL 9.00 Decreased By ▼ -0.04 (-0.44%)
HUBC 79.00 Increased By ▲ 4.80 (6.47%)
HUMNL 5.84 Decreased By ▼ -0.04 (-0.68%)
JSCL 18.70 Increased By ▲ 0.50 (2.75%)
KAPCO 39.39 Increased By ▲ 1.38 (3.63%)
KEL 3.68 Increased By ▲ 0.09 (2.51%)
LOTCHEM 14.35 Increased By ▲ 0.25 (1.77%)
MLCF 42.30 Increased By ▲ 0.05 (0.12%)
PAEL 31.07 Increased By ▲ 0.07 (0.23%)
PIBTL 9.45 Increased By ▲ 0.13 (1.39%)
POWER 8.44 Increased By ▲ 0.22 (2.68%)
PPL 83.30 Increased By ▲ 1.80 (2.21%)
PRL 22.77 Increased By ▲ 0.23 (1.02%)
PTC 9.20 Increased By ▲ 0.16 (1.77%)
SILK 1.40 Increased By ▲ 0.03 (2.19%)
SNGP 38.59 Increased By ▲ 0.49 (1.29%)
TRG 163.22 Decreased By ▼ -5.12 (-3.04%)
UNITY 34.93 Increased By ▲ 0.47 (1.36%)
WTL 1.45 Decreased By ▼ -0.04 (-2.68%)
BR100 4,799 Increased By ▲ 39.91 (0.84%)
BR30 24,693 Increased By ▲ 286.81 (1.18%)
KSE100 44,944 Increased By ▲ 380.02 (0.85%)
KSE30 18,383 Increased By ▲ 122.64 (0.67%)

Coronavirus
VERY HIGH
Pakistan Deaths
18,429
11924hr
Pakistan Cases
841,636
411324hr
Sindh
287,643
Punjab
310,616
Balochistan
22,776
Islamabad
76,696
KPK
121,099
Business & Finance

Indian drugmaker Biological E. starts human trials of COVID-19 vaccine candidate

  • The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.
  • India has reported 8.85 million confirmed cases of the virus - the second highest in the world,
16 Nov 2020

BENGALURU: India's Biological E. Ltd has started human trials of its COVID-19 vaccine candidate and expects results by February, the drugmaker said on Monday.

The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate - being developed with Baylor College of Medicine in Houston, Texas, and US-based Dynavax Technologies Corp - after getting the green signal from the Drugs Controller General of India.

The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.

Separately, Bharat Biotech, a private company developing a vaccine candidate, COVAXIN, with the government-run Indian Council of Medical Research, said it was starting phase III trials on Monday.

India has reported 8.85 million confirmed cases of the virus - the second highest in the world, after the United States - but the number of new daily cases has fallen since a peak in mid-September.

Meanwhile, hopes for a vaccine got a fresh boost after US-based Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial.

Last week, drugmaker Pfizer Inc and German partner BioNTech SE said their vaccine was more than 90% effective.

An Indian government-backed vaccine could be launched as early as February - months earlier than expected - as last-stage trials begin this month, a senior government scientist previously told Reuters.